1-Feb-2023	Edison report: Reinvestment period with increased R&D focus

1-Nov-2022	Edison report: Q1 23 cash flows in line with our estimates

28-Oct-2022	New melanoma breakthrough by Kazia could potentially save thousands of lives

10-Oct-2022	Edison report: PNOC022 trial expanded

5-Sep-2022	Edison report: Doubling down on clinical development

8-Aug-2022	Interim data from MSKCC study

1-Aug-2022	GBM Agile Update

20-Jul-2022	Kazia recognises GBM Awareness Day 2022 as it expands clinical trial activity in Europe and US

12-Jul-2022	Kazia launches new SAB

17-Jun-2022	FDA AWARDS ORPHAN DESIGNATION TO PAXALISIB FOR ATRT

14-Jun-2022	Kazia paxalisib preclinical DIPG data released at IPSNO

8-Jun-2022	Kazia's Alliance study progresses to expansion phase

3-Jun-2022	Kazia presents final PII data at ASCO

31-May-2022	GBM Agile opens to paxalisib in Europe

24-May-2022	Edison Research: Deep Dive into Childhood Brain Cancer

23-May-2022	Kazia to present at investor conferences hosted by HC Wainwright and LD Micro

17-May-2022	Kazia marks DIPG Awareness Day

17-May-2022	Interview with Dr Matt Dun for World DIPG Awareness Day

29-Apr-2022	Kazia to present at ASCO

8-Apr-2022	Kazia presents preclinical data for paxalisib at AACR

8-Apr-2022	Kazia presents on EVT801 at AACR

21-Mar-2022	Kazia to present at two conferences

28-Feb-2022	First patient into Cornell keto study

31-Jan-2022	Quarterly Activities Report And Appendix 4c

19-Jan-2022	Kazia Corporate Presentation

7-Jan-2022	Kazia Therapeutics To Present At Hc Wainwright Bioconnect Conference

13-Dec-2021	Kazia Therapeutics Appoints Karen Krumeich As Chief Financial Officer

3-Dec-2021	Kazia Announces Positive Final Data From Phase Ii Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma

29-Nov-2021	Gbm Agile Opens To Paxalisib In Canada

15-Nov-2021	Kazia Therapeutics Appoints John Friend, Md, As Chief Medical Officer

11-Nov-2021	Pnoc Study In Childhood Brain Cancer Enrols First Patient

10-Nov-2021	Kazia Annual General Meeting Results

4-Nov-2021	Kazia Annual General Meeting Results

29-Oct-2021	Quarterly Activities Report And Appendix 4c

10-Sep-2021	Kazia Therapeutics To Present At Hc Wainwright 23rd Annual Global Investment Conference

2-Sep-2021	Evt801 Phase I Study Receives Full Regulatory Approval

30-Jul-2021	Quarterly Activities Report And Appendix 4c

21-Jul-2021	Kazia Calls For Increased Focus On Brain Cancer Research This Gbm Awareness Day

30-Jun-2021	Kazia Provides Progress Update On Paxalisib And Evt801 Clinical Programs

24-Jun-2021	Manufacturing Patents Granted For Paxalisib In Key Territories; Extend Effective Patent Protection To 2036

15-Jun-2021	Kazia Enters Clinical Collaboration With Cornell University For Phase Ii Clinical Study Using Paxalisib In Combination With Ketogenic Diet For Glioblastoma

7-Jun-2021	Study Of Paxalisib In Primary Cns Lymphoma At Dana-Farber Cancer Institute Enrols First Patient

19-Apr-2021	Kazia Licenses Global Rights To Evt801, A Novel, First-In-Class, Clinic-Ready, Vegfr3 Inhibitor, From Evotec Se

29-Mar-2021	Kazia Licenses Rights To Paxalisib In Greater China To Simcere, A Leading Chinese Pharmaceutical Company

1-Mar-2021	Kazia Licenses Cantrixil, A Clinical-Stage, First-In-Class Ovarian Cancer Drug Candidate, To Oasmia Pharmacetical Ab

7-Jan-2021	Gbm Agile Pivotal Study Commences Recruitment To Paxalisib Arm

20-Dec-2020	Kazia Therapeutics Limited Appendix 4D Half-year report